Table 1

Baseline characteristics of the patients

Control groupContinuous monitoring group
N5862
Female sex, number (%)19 (33)26 (42)
Age (years)*26.0 ± 14.625.7 ± 14.1
Pediatric, number (%)26 (45)27 (44)
BMI (kg/m2)*22.0 ± 3.822.4 ± 3.8
Duration of diabetes (years)*11.4 ± 11.411.6 ± 11.3
Insulin administration, number (%)
 Pump34 (59)47 (76)
 MDI24 (41)15 (24)
Glycated hemoglobin at screening (%)*6.90 ± 0.476.83 ± 0.44
Glycated hemoglobin at baseline (%)*6.91 ± 0.676.92 ± 0.56
Record of severe hypoglycemia in last year, number (%)7 (12)5 (8)
Diagnosed with hypoglycemia unawareness, number (%)4 (7)6 (10)
Daily insulin dose (units/kg)*0.67 ± 0.320.66 ± 0.25
Education, number (%)
 Pediatric patient still in education26 (45)29 (47)
 Completed education by age 183 (5)6 (10)
 Completed further education29 (50)27 (44)
Prior use of continuous glucose monitor, number (%)18 (31)21 (34)
Mean blood glucose in 1-month run-in period (mg/dL)*148 ± 28147 ± 23
SMBG measurements per day in 1-month run-in period*5.1 ± 2.55.3 ± 2.2
  • Differences between the control and the continuous monitoring group were not statistically significant. MDI, multiple daily injection.

  • *Means ± SD.